葛兰素史克Glaxosmithkline plc (GSK) 2023年年度报告「LSE」.pdf

1、 At GSK,we unite science,technology and talent toget ahead of disease together.We aim to positively impact the health of 2.5 billion peopleby the end of the decade,as a successful,growing companywhere people can thrive.ContentsStrategic reportAhead Together012023 performance and key performance indi

2、cators02Chairs statement04CEOs statement06Business model08Our external environment10Prevention13Our culture and people14Research and development16Commercial operations:31Performance:Vaccines33Performance:Specialty Medicines37Performance:General Medicines40Operations:Manufacturing andsupply43Responsi

3、ble business45Risk management and disclosure statements572023 principal risks summary59Climate-related financial disclosures62Nature-related financial disclosures70Non-financial and sustainability information statement75Employees by gender75Viability statement76Group financial review77Corporate gove

4、rnanceThe Board and GSK Leadership Team108Chairs governance statement114Corporate governance architecture116Ahead Together Board oversight119Continuous engagements and key decisions121Board committee reports128Remuneration Committee Chairs annual statement139Annual report on remuneration142Directors

5、 report161Financial statementsDirectors statement ofresponsibilities164Independent auditors report166Financial statements180Notes to the financial statements 184Financial statements of GSK plc prepared under UK GAAP267Investor informationFinancial record273Product development pipeline277Products,com

6、petition andintellectual property281Principal risks and uncertainties284Share capital and control295Dividends297Financial calendar 2024298Annual General Meeting 2024298Tax information for shareholders299Shareholder services and contacts301US law and regulation303Group companies306Glossary of terms31